A statement released earlier today by Laidlaw about VBI Vaccines (NASDAQ:VBIV) raises the target price to $6.00
- Updated: October 9, 2016
Laidlaw upped the price target of VBI Vaccines (NASDAQ:VBIV) to $6.00 indicating a possible upside of 0.88%.
Yesterday VBI Vaccines (NASDAQ:VBIV) traded 0.00% even at $3.19. VBI Vaccines’s 50-day average is $3.70 and its two hundred day average is $3.83. With the last close down -16.70% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same time. 48,009 shares of VBI Vaccines exchanged hands, down from an avg. volume of 73,575
See Chart Below
VBI Vaccines has one year low of $3.07 and a one year high of $4.40 and has a market cap of $0.
Brief Synopsis About VBI Vaccines (NASDAQ:VBIV)
VBI Vaccines Inc., formerly Paulson Capital Corp., is a biopharmaceutical company. The Company is engaged in the formulation, development and delivery of vaccines that expand and enhance vaccine protection. The Company's eVLP vaccine platform allows for the design of enveloped (e) virus-like particle (VLP) vaccines that closely mimic the target virus. The company's lead eVLP asset is a prophylactic Cytomegalovirus (CMV) vaccine. The Company has initiated work for manufacturing of its CMV candidate for use in formal preclinical and Phase I trials. The company's Lipid Particle Vaccine technology (LPV) is a vaccine formulation technology that enables the thermostabilization of vaccines through a formulation and freeze-drying process. The company has completed proof of concept thermostability studies on a number of vaccine and biologic targets.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.